BiotechTube

HTL0009936 + HTL0009936 matching placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Oct 1, 2015 → Feb 1, 2017

NCT ID
NCT02546310

About HTL0009936 + HTL0009936 matching placebo

HTL0009936 + HTL0009936 matching placebo is a phase 1 stage product being developed by Nxera Pharma for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02546310. Target conditions include Alzheimer's Disease.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02546310Phase 1Completed

Competing Products

20 competing products in Alzheimer's Disease

See all competitors
ProductCompanyStageHype Score
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
GSK4527226AlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
simufilamCassava SciencesPhase 2
44
Remternetug + PlaceboEli LillyPhase 3
77
solanezumabEli LillyPhase 2
52
LY2886721 + PlaceboEli LillyPhase 1
33
Gantenerumab + Gantenerumab + Gantenerumab + PlaceboChugai PharmaceuticalPhase 1
33
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
85
FK962Astellas PharmaPhase 2
52
ASP0777 + PlaceboAstellas PharmaPhase 1
33
Elenbecestat + PlaceboEisaiPhase 3
77
DonepezilEisaiApproved
85
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)EisaiPhase 3
77
Donepezil hydrochlorideEisaiPhase 3
77
Donepezil HydrochlorideEisaiPre-clinical
23

Other Products from Nxera Pharma

Daridorexant + PlaceboPhase 3
76
HTL0018318 + PlaceboPhase 2
51
HTL0039732 Capsules + HTL0039732 Capsules and atezolizumab infusionPhase 1/2
40
HTL0018318Phase 1
32
HTL0018318 + Placebo oral capsulePhase 1
32